Breast cancer Drug's hidden heart risks under the microscope
NCT ID NCT06781762
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks 40 postmenopausal women with hormone-positive breast cancer who are starting aromatase inhibitor therapy. Researchers will measure heart and blood vessel health, blood markers, body composition, and lifestyle factors over 6 months, comparing them to healthy women of the same age and weight. The goal is to understand why these drugs increase heart risks over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aromatase inhibitors
What this could lead to
If successful, this study could help doctors better monitor and prevent heart problems in breast cancer patients taking aromatase inhibitors.
What could go wrong
This is a small observational study with only 40 participants, so results may not apply to everyone. It does not test a new treatment, only measures existing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Toronto
RECRUITINGToronto, Ontario, M5S2C9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••